Hansa Biopharma ABOSTO:HNSA -1.25%49 Median PS Value is kr1,033.59 as of Jun. 29, 2026, which is 100% below its 10-year median of 0.03. GuruFocus rates OSTO:HNSA with a GF Score™ of 49/100 and a GF Value™ of kr24.55 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 277 Biotechnology companies, Hansa Biopharma AB ranks better than 98.19% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Hansa Biopharma AB's Median PS Value or its related term are showing as below:
OSTO:HNSA'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.02 Med: 0.03 Max: 0.03
Current: 0.03
During the past 13 years, the highest Price to Median PS Value of Hansa Biopharma AB was 0.03. The lowest was 0.02. And the median was 0.03.
OSTO:HNSA's Price-to-Median-PS-Value is ranked better than 98.19% of 277
companies
in the Biotechnology industry
Industry Median: 0.62
vs OSTO:HNSA: 0.03
Hansa Biopharma AB (OSTO:HNSA) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Hansa Biopharma AB's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
33.10
/
1,033.59
=
0.03
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansa Biopharma AB Median PS Value Related Terms
Hansa Biopharma AB Median PS Value Historical Data
* Premium members only.
The historical data trend for Hansa Biopharma AB's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:HNSA vs VRTX, REGN, ALNY: Median PS Value Comparison
For the Biotechnology subindustry, Hansa Biopharma AB's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansa Biopharma AB Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Hansa Biopharma AB's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 482.0849.
Hansa Biopharma AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr2.144.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansa Biopharma AB (OSTO:HNSA) has a Median PS Value of kr1,033.59 as of Jun. 29, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Hansa Biopharma AB and its competitors. This is 3445200% above median its historical median of 0.03. Over the past decade, Hansa Biopharma AB's Median PS Value has ranged from 0.02 to 0.03. According to the industry distribution chart, Hansa Biopharma AB ranks #5 out of 277 companies in the Biotechnology industry, placing it in the top 1.8%.
Is Hansa Biopharma AB's Median PS Value too high?
Hansa Biopharma AB's current Median PS Value of kr1,033.59 is 3445200% above median its 10-year median of 0.03. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.03. Based on the distribution chart, Hansa Biopharma AB ranks #5 out of 277 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Hansa Biopharma AB has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hansa Biopharma AB ranks #5 out of 277 companies for Median PS Value. This places Hansa Biopharma AB in the top 2% of its industry — outperforming the majority of peers. The industry median Median PS Value is 0.62. Historically, Hansa Biopharma AB's own Median PS Value has ranged from 0.02 to 0.03 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.62, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Hansa Biopharma AB and its competitors. For the Biotechnology industry, the median Median PS Value is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hansa Biopharma AB's current Median PS Value is kr1,033.59, which is 3445200% above median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Hansa Biopharma AB (OSTO:HNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is kr24.55, compared to a current price of kr33.10 — trading 34.8% above its estimated fair value. The current Median PS Value is kr1,033.59, which is 3445200% above median its 10-year median of 0.03. Hansa Biopharma AB's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Hansa Biopharma AB (OSTO:HNSA), the current Median PS Value is kr1,033.59 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansa Biopharma AB (OSTO:HNSA) Overvalued in 2026?
Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued.
The current stock price of kr33.10 is trading 34.8% above its estimated GF Value™ of kr24.55.
GuruFocus considers Hansa Biopharma AB to be Significantly Overvalued.
Key valuation signals for OSTO:HNSA:
Median PS Value: kr1,033.59 (3445200% above median its 10-year median of 0.03)
GF Value™: kr24.55 vs. price of kr33.10 (34.8% above fair value)
No single metric tells the full story. See the OSTO:HNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
49GF Score
Get the complete analysis for OSTO:HNSA
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:HNSA has been successfully added to your 
